Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables - Net: 2010-2024

Historic Receivables - Net for Heron Therapeutics (HRTX) over the last 10 years, with Dec 2024 value amounting to $78.9 million.

  • Heron Therapeutics' Receivables - Net rose 20.90% to $81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.0 million, marking a year-over-year increase of 20.90%. This contributed to the annual value of $78.9 million for FY2024, which is 31.17% up from last year.
  • Per Heron Therapeutics' latest filing, its Receivables - Net stood at $78.9 million for FY2024, which was up 31.17% from $60.1 million recorded in FY2023.
  • Heron Therapeutics' Receivables - Net's 5-year high stood at $78.9 million during FY2024, with a 5-year trough of $35.5 million in FY2021.
  • Its 3-year average for Receivables - Net is $63.7 million, with a median of $60.1 million in 2023.
  • In the last 5 years, Heron Therapeutics' Receivables - Net declined by 15.18% in 2021 and then surged by 46.62% in 2022.
  • Yearly analysis of 5 years shows Heron Therapeutics' Receivables - Net stood at $41.9 million in 2020, then declined by 15.18% to $35.5 million in 2021, then surged by 46.62% to $52.0 million in 2022, then climbed by 15.54% to $60.1 million in 2023, then soared by 31.17% to $78.9 million in 2024.